Navigation Links
Arno Therapeutics Appoints William F. Hamilton to Board of Directors

FAIRFIELD, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI.OB), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the appointment of William F. Hamilton, Ph.D. to its Board of Directors and as chairman of the audit committee. Dr. Hamilton has over 40 years experience as a professor at The Wharton School with particular expertise in the areas of technology strategy and planning, entrepreneurship and technological innovation.

Dr. Hamilton, 69, has served on the University of Pennsylvania faculty since 1967, and is the Landau Professor of Management and Technology, and Director of the Jerome Fisher Program in Management and Technology at The Wharton School and the School of Engineering and Applied Science. As a co-founder and Director of Research, and later as Associate Director of the Institute of Health Economics, he led development of the interdisciplinary research program which was selected in nationwide competition as the National Center for Management Research in the health field. He serves as a director of NovaDel Pharma Inc., Avid Radiopharmaceuticals, Inc., Yaupon Therapeutics, Inc., Neuro Diagnostic Devices, Inc. and Neose Technologies, Inc. Dr. Hamilton received his B.S. and M.S. in chemical engineering and his MBA from the University of Pennsylvania, and his Ph.D. in applied economics from the London School of Economics.

Arie S. Belldegrun, M.D., FACS, Chairman of the Board of Directors of Arno, said, "Bill brings to Arno an impressive track record from a distinguished career in academia. We are confident that his extensive expertise in strategic management, technological innovation and entrepreneurship will be of great benefit to Arno's Board of Directors and senior management team."

Roger G. Berlin, M.D., Chief Executive Officer or Arno added "We are extremely pleased to welcome to our Board an executive with Bill's outstanding leadership abilities and expertise in technology development and innovation. Bill's insight into the complexities of biotechnology innovation and development will be invaluable in helping us achieve our strategic goals."

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel third-generation camptothecin analogue in Phase I studies in patients with advanced solid tumors that has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including those described under the caption "Risk Factors" in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2008. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
2. Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
3. ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units
4. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
5. Synvista Therapeutics Appoints William Federici to its Board of Directors
6. LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster
7. Cell Therapeutics Regains Compliance with NASDAQs Minimum Bid Price Requirement
8. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
9. Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
10. Afid Therapeutics Inc.s New Anticoagulant Heparin Replacement Passes in Vivo Test
11. Industry Experts and Global Regulators to Discuss Oligonucleotide-Based Therapeutics Issues
Post Your Comments:
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... accessible for all, Water For Empowerment ™ attracts volunteers together who want ... water by empowering women as key stakeholders in the process. The non-profit launched ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 ... ... manufacturer, launched offering factory direct sauna parts and accessories. , Sauna accessories ... representative of the bather’s style and personality. From basic styles for the purist ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... OK (PRWEB) , ... November 25, 2015 , ... On ... International training center for the Narconon network, announced the release of a new cutting ... 1966 the Narconon organization has been working with drug- and alcohol-addicted individuals with the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... YORK , November 25, 2015 ... market of self-monitoring blood glucose devices was valued at ... grow with a CAGR of 5.7% during 2015 - ... geriatric population and increasing prevalence of diabetes. In addition, ... diabetes care is also contributing to the growth of ...
(Date:11/25/2015)... -- Developmental, commercial, and regulatory/legal strategies ... pharmaceutical products, says GBI Research . ... all play a key role in boosting the profitability ... . --> Developmental, commercial, and ... the profitability of pharmaceutical products, says GBI Research ...
(Date:11/25/2015)... Frankreich, November 25, 2015 ... dass sie eine Lizenz für das Patent über eine ... UCBL und ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... AAP8 ins Leben gerufenen und von Edelris gemeinsam mit ... als ein Behandlungsziel für HBV identifiziert, und es wurden ...
Breaking Medicine Technology: